食管鳞状细胞癌（SqCC）的治疗管理在过去十年中发生了显著变化，新型手术技术的发展，如早期浅表食道癌的内镜下粘膜切除术以及现有手术技术的改进（例如Ivor-Lewis食管切除术）与患者结局的改善有关。来自CROSS研究的数据已经确立新辅助化疗放疗（CRT）作为对局部晚期疾病进展至食管切除术的标准治疗。同时，定义性化疗放疗（dCRT）作为一种有效的治疗模式已经出现，并带有器官保留的附加优势。本综述重点回顾局限性食管SqCC的管理，并探讨不同治疗模式的疗效和注意事项的证据。其中一个关键目标是识别可能影响选择特定模式（例如：手术与dCRT）的特定特征，并制定适用于早期（浅表）和局部晚期食管SqCC的基于证据的管理算法。版权所有 © 2023 Elsevier B.V.，由Elsevier B.V.出版。保留所有权利。

The management of squamous cell carcinoma (SqCC) of esophagus has significantly changed over last decade with the development of newer surgical techniques such as endoscopic submucosal dissection for early superficial esophageal cancer and refinement of existing surgical techniques (e.g., Ivor-Lewis esophagectomy) that has been associated with an improvement in patient outcomes. The data from the pivotal CROSS study has established neoadjuvant chemoradiotherapy (CRT) as standard of care for patients with locally advanced disease progressing to esophagectomy Simultaneously, definitive chemoradiotherapy (dCRT) has emerged as an effective therapeutic modality with an added advantage of organ preservation. The present review focuses on reviewing the management of localized esophageal SqCC and exploring the evidence regarding the efficacy and caveats of different therapeutic modalities. One of the key objectives is to identify any specific features which may influence choosing a particular modality (e.g. surgery cf. dCRT) and definition of an appropriate evidence-based algorithm for management of early (superficial) and locally advanced SqCC of esophagus.Crown Copyright © 2023. Published by Elsevier B.V. All rights reserved.